Perhaps since women tend to have higher CRP levels but generally lower CHD risks [27], JUPITER was not the most cost-effective risk stratification approach in women as it placed twice the number of women on statins compared to any other risk-stratification approach. The gene discussed is CRP; the disease is coronary artery disorder.